Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  Beleave Inc    BE   CA0775611084

BELEAVE INC (BE)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 02/21 10:04:59 pm
2.03 CAD   -4.69%
01/04BELEAVE : Announces Issuance of Options
MW
2017BELEAVE : IIROC Trade Resumption - BE
AQ
2017BELEAVE : IIROC Trading Halt - BE
AQ
SummaryQuotesChartsNewsCalendarCompanyConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Beleave : Announces Issuance of Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/04/2018 | 01:35pm CET

TORONTO, ONTARIO--(Marketwired - Jan 4, 2018) - Beleave Inc. ("Beleave" or the "Company") (CSE:BE)(CSE:BE.CN)(CSNX:BE)(OTCQX:BLEVF) announces that it has granted 1,350,000 stock options to purchase common shares (the "Options") to the directors and management team members of Beleave in accordance with the Company's stock option plan. Each option is exercisable to purchase one common share of the Company at $3.00 per common share. All Options vest immediately and have a five-year term.

All common share and option issuances are subject to applicable regulatory approvals (including the Canadian Securities Exchange).

About Beleave

Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.


© Marketwired 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BELEAVE INC
01/04BELEAVE : Announces Issuance of Options
MW
2017BELEAVE : IIROC Trade Resumption - BE
AQ
2017BELEAVE : IIROC Trading Halt - BE
AQ
2017BELEAVE : Signs Brand Licensing Agreement with Kevin Smith & Jason Mewes
AQ
2017BELEAVE : Closes $9.95 Million Non-Brokered Private Placement of Units
AQ
2017BELEAVE : Announces Upsize of Previously Announced Non-Brokered Private Placemen..
MW
2017BELEAVE : Aims to Raise Awareness by Supporting Don't Drive High Campaign
MW
2017BELEAVE : and Dr. Michael Rogers Begin Research in Cannabis Food and Drug Delive..
AQ
2017CANNABIS WHEATON INCOME : REPEAT - Cannabis Wheaton Provides Initial Advance of ..
AQ
2017CANNABIS WHEATON INCOME : Provides Initial Advance of $5,000,000 to Beleave
AQ
More news
Financials ( CAD)
Sales 2017 -
EBIT 2017 -4,80 M
Net income 2017 -4,80 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 0
Capi. / Sales 2018 -
Capitalization -
Chart BELEAVE INC
Duration : Period :
Beleave Inc Technical Analysis Chart | BE | CA0775611084 | 4-Traders
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price -
Spread / Average Target
EPS Revisions
Managers
NameTitle
Andrew T. Wnek Chief Executive Officer
Roger Ferreira President, Chief Science Officer & Director
Vasilios Panagiotakopoulos Chief Operational Officer & Director
Bojan Krasic Chief Financial Officer & Director
Christopher Robin Murphy Director & Head-Distribution & Operations
Sector and Competitors
1st jan.Capitalization (M$)
BELEAVE INC-23.68%0
GILEAD SCIENCES14.21%105 702
VERTEX PHARMACEUTICALS4.94%40 647
REGENERON PHARMACEUTICALS-12.04%35 686
BIOVERATIV INC91.99%11 211
GENMAB4.28%10 637